Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EUROSTAM

Financiado

Cerrado

A Europe wide Strategy to enhance Transplantation of highly sensitized patients...

A Europe wide Strategy to enhance Transplantation of highly sensitized patients on basis of Acceptable HLA Mismatches The presence of donor specific HLA antibodies is a contra-indication for renal transplantation. Highly sensitized patients accumulate and often die on the transplant waiting lists as it is almost impossible to find donors towards... ver más

30/11/2015

Leiden University...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 10 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-11-30 No tenemos la información de la convocatoria

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

10 Participantes

Leiden University Medical Ce...

0.00€ | Lider

CONSORCI INSTITUT D INVESTIG...

N.D. | Participante

NHSBT

N.D. | Participante

ASSISTANCE PUBLIQUE HOPITAUX...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Histogenomics Novel histocompatibility loci in man 3M€ Cerrado

KiT-FIG Kidney Transplantation Functional ImmunoGenomics 197K€ Cerrado

BFU2009-11826 ESTUDIO LAS CELULAS TH17 EN LA PATOGENIA DE LA ENFERMEDAD IN... 42K€ Cerrado

SAF2015-64224-R ENDOTELIZACION INTER-ESPECIES COMO ESTRATEGIA PARA LA REALIZ... 121K€ Cerrado

VISICORT Adverse Immune Signatures and their Prevention in Corneal Tr... 8M€ Cerrado

EU-TRAIN The EUropean TRAnsplantation and INnovation EU TRAIN conso... 7M€ Cerrado

Líder del proyecto

ACADEMISCH ZIEKENHUIS LEIDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The presence of donor specific HLA antibodies is a contra-indication for renal transplantation. Highly sensitized patients accumulate and often die on the transplant waiting lists as it is almost impossible to find donors towards which they don’t have antibodies. The acceptable mismatch program of Eurotransplant has shown to be an effective tool to enhance successful transplantation of highly sensitized patients. However, 35% of the patients have rare HLA phenotypes and no suitable donor can be found. HLA phenotype frequencies vary amongst European populations. Rare HLA phenotypes in one population are more frequent in other populations. The major objective of the 10 partners in this project is to analyze the feasibility and requirements for a Europe-wide acceptable mismatch program to enhance transplantation of patients with rare HLA phenotypes in their own population. Long waiting patients will be matched with virtual donors based on known HLA frequencies of different European populations and with actual donors from the different transplant organizations. If successful, the logistics will be tested by transplanting some of these patients with donors from elsewhere in Europe. Second objective is to simplify the definition of acceptable HLA mismatches. Although almost 4000 HLA class I antigens are known, only 150 polymorphic residues differentially spread over the different HLA antigens are responsible for the induction of antibodies. An innovative typing and matching strategy based on the definition of acceptable HLA epitopes will facilitate the identification of suitable donors. Third objective is to define whether antibodies against non-HLA targets on the donor endothelium affect the results of transplants in highly sensitized patients. The aims of this collaborative project are fully compatible with those required for the program Health.2012.1.4-1. In objectives 2 and 3 two partners belonging to the SME sector of the European industry are involved.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores